Sawai Launches Eight Generic Drugs with 23 Strengths

Jun. 17. 2021

Osaka, Japan - June 17, 2021 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the launch of eight generic drugs with 23 strengths. They will be launched sequentially beginning June 18, 2021. Sawai’s product line now includes 327 compounds with 808 strengths.

The list of new products

1. Eszopiclone Tablets

Generic name Eszopiclone
Strengths 1mg, 2mg, 3mg
Brand products Lunesta® Tablets 1mg, 2mg, 3mg

2. Solifenacin Succinate Tablets, OD Tablets

Generic name Solifenacin Succinate
Strengths Tablets, OD Tablets: 2.5mg, 5mg
Brand products Vesicare® Tablets 2.5mg, 5mg, Vesicare® OD Tablets 2.5mg, 5mg

3. Zilmlo® Combination Tablets, OD Tablets

Generic name Azilsartan, Amlodipine
Strengths LD, HD
Brand products ZACRAS® Combination Tablets LD&HD

4. Epinastine Hydrochloride Ophthalmic Solution

Generic name Epinastine Hydrochloride
Strengths 0.05%
Brand products ALESION® Ophthalmic Solution 0.05%

5. Duloxetine Capsules

Generic name Duloxetine Hydrochloride
Strengths 20mg, 30mg
Brand products Cymbalta® Capsules 20mg, 30mg

6. Tadalafil Tablets AD

Generic name Tadalafil
Strengths 20mg
Brand products Adcirca® Tablets 20mg

7. Pemetrexed for Intravenous Infusion, Intravenous Infusion

Generic name Pemetrexed
Strengths For Intravenous Infusion 100mg, 500mg, 800mg,
Intravenous Infusion 100mg, 500mg, 800mg
Brand products Alimta® Injection 100mg, 500mg

8. Deferasirox Granules

Generic name Deferasirox
Strengths 90mg, 360mg
Brand products JADENU® Granules Sachet 90mg, 360mg


The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.